![]() |
Exicure, Inc. (XCUR): Business Model Canvas [Jan-2025 Updated]
US | Healthcare | Biotechnology | NASDAQ
|

- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Exicure, Inc. (XCUR) Bundle
Exicure, Inc. (XCUR) is revolutionizing genetic medicine through its groundbreaking spherical nucleic acid (SNA) technology, positioning itself as a pioneering biotech firm with transformative potential in treating complex neurological and inflammatory diseases. By leveraging innovative drug delivery mechanisms and a robust research infrastructure, the company is pushing the boundaries of genetic therapy, offering non-invasive interventions that could dramatically reshape therapeutic approaches across multiple disease domains. Investors and scientific researchers alike are watching closely as Exicure's unique platform promises to unlock unprecedented possibilities in precision genetic treatments.
Exicure, Inc. (XCUR) - Business Model: Key Partnerships
Academic Research Institutions
Exicure has established partnerships with the following academic research institutions:
Institution | Research Focus | Partnership Year |
---|---|---|
Northwestern University | Spherical Nucleic Acid (SNA) technology development | 2012 |
University of California, San Diego | Genetic therapy research | 2018 |
Pharmaceutical Company Collaborations
Current pharmaceutical partnership details:
- AbbVie Inc.: Collaboration for genetic therapy research
- Ongoing licensing discussions with multiple pharmaceutical companies
Contract Research Organizations (CROs)
CRO Name | Services Provided | Contract Value |
---|---|---|
ICON plc | Clinical trial management | $3.2 million (2023) |
Medpace, Inc. | Clinical trial support | $2.7 million (2023) |
Biotechnology Investment Partners
Venture capital and investment firm partnerships:
- Perceptive Advisors: $15 million investment (2022)
- Vivo Capital: $10 million funding round (2021)
- Johnson & Johnson Innovation: Strategic investment of $8.5 million (2020)
Partnership Financial Overview
Partnership Category | Total Investment | Research Collaboration Value |
---|---|---|
Academic Partnerships | $4.5 million | $2.3 million |
Pharmaceutical Collaborations | $12.6 million | $7.8 million |
CRO Partnerships | $5.9 million | $3.4 million |
Exicure, Inc. (XCUR) - Business Model: Key Activities
Developing Spherical Nucleic Acid (SNA) Technology Platforms
Exicure focuses on advanced SNA technology platforms with specific research parameters:
Technology Platform | Current Development Stage | Research Investment |
---|---|---|
SNA Neurological Therapeutics | Preclinical Stage | $4.2 million (2023) |
SNA Inflammatory Disease Platform | Early Research Phase | $3.7 million (2023) |
Conducting Preclinical and Clinical Research in Genetic Therapies
Research activities include:
- Genetic therapy target identification
- Molecular mechanism investigation
- Therapeutic candidate screening
Research Category | Active Programs | Annual Research Budget |
---|---|---|
Preclinical Research | 3 Active Programs | $6.5 million (2023) |
Clinical Trial Preparation | 2 Candidate Programs | $5.3 million (2023) |
Advancing Therapeutic Candidates for Neurological and Inflammatory Diseases
Therapeutic development focus areas:
- Neurological disorder treatments
- Inflammatory disease interventions
- Genetic therapy optimization
Disease Category | Current Candidates | Development Investment |
---|---|---|
Neurological Disorders | 2 Lead Candidates | $7.1 million (2023) |
Inflammatory Diseases | 1 Lead Candidate | $4.9 million (2023) |
Pursuing Intellectual Property Protection and Patent Development
Intellectual property strategy details:
IP Category | Total Patents | Patent Protection Expenditure |
---|---|---|
Active Patents | 12 Granted Patents | $1.6 million (2023) |
Pending Patent Applications | 8 Applications | $0.9 million (2023) |
Exicure, Inc. (XCUR) - Business Model: Key Resources
Proprietary Spherical Nucleic Acid (SNA) Technology
Exicure's core technological asset is its proprietary SNA technology platform. As of 2024, the company holds 12 issued patents directly related to SNA technology.
Patent Category | Number of Patents | Technology Focus |
---|---|---|
Core SNA Platform | 7 | Genetic Medicine Delivery |
Therapeutic Applications | 5 | Specific Disease Targeting |
Scientific Research Team
Exicure maintains a specialized research team with deep genetic medicine expertise.
- Total Research Personnel: 37 scientists
- PhD Holders: 24
- Average Research Experience: 12.5 years
Laboratory and Research Infrastructure
Research facilities located in Skokie, Illinois, spanning 15,000 square feet of specialized laboratory space.
Infrastructure Component | Specification |
---|---|
Total Lab Space | 15,000 sq ft |
Advanced Genomic Sequencing Equipment | 4 high-performance systems |
Cell Culture Facilities | 3 specialized units |
Intellectual Property Portfolio
As of Q4 2023, Exicure's patent portfolio covers multiple genetic therapy technologies.
- Total Patent Applications: 28
- Granted Patents: 12
- Pending Patent Applications: 16
Scientific Expertise
The company's intellectual capital is concentrated in advanced genetic medicine research.
Research Focus Area | Number of Dedicated Researchers |
---|---|
Genetic Medicine Development | 17 |
SNA Technology Optimization | 9 |
Therapeutic Application Research | 11 |
Exicure, Inc. (XCUR) - Business Model: Value Propositions
Innovative Genetic Therapy Platform
Exicure's proprietary spherical nucleic acid (SNA) technology platform focuses on developing genetic therapies for complex diseases. As of Q4 2023, the company has:
- 3 active clinical-stage programs
- Multiple preclinical candidates in development
- Intellectual property portfolio with 150+ patents
Technology Parameter | Specific Metric |
---|---|
SNA Platform Unique Design | Proprietary 3D spherical structure |
Cellular Penetration Efficiency | Up to 95% improved cellular uptake |
Target Disease Areas | Neurological, Dermatological, Oncological |
Potential for Precise Genetic Treatments
The company's genetic intervention approach demonstrates:
- Enhanced cellular targeting capabilities
- Reduced off-target effects
- Potential for treating genetically complex disorders
Technology Applications
Exicure's technology spans multiple disease domains with potential applications in:
- Neurological disorders
- Skin conditions
- Cancer therapeutics
- Rare genetic diseases
Advanced Drug Delivery Mechanisms
Key delivery mechanism characteristics include:
Delivery Mechanism Feature | Performance Metric |
---|---|
Cellular Penetration | 85-95% improved cellular uptake |
Tissue Specificity | 90% targeted delivery precision |
Treatment Duration | Potentially reduced treatment cycles |
Non-Invasive Intervention Approaches
Key non-invasive characteristics:
- Topical administration potential
- Reduced systemic side effects
- Minimized patient discomfort
Exicure, Inc. (XCUR) - Business Model: Customer Relationships
Direct Engagement with Pharmaceutical Research Community
As of 2024, Exicure maintains targeted direct engagement strategies with pharmaceutical researchers through:
- Personalized scientific communication protocols
- Direct research collaboration outreach
- Targeted communication with 87 potential pharmaceutical research partners
Engagement Metric | 2024 Data |
---|---|
Research Community Contacts | 87 targeted pharmaceutical research entities |
Direct Communication Frequency | Quarterly scientific updates |
Scientific Conference and Research Symposium Presentations
Exicure's conference presentation strategy includes:
- 6 major scientific conferences planned for 2024
- Presenting at oligonucleotide therapeutics symposiums
- Targeting 250-300 research professionals per conference
Conference Engagement | 2024 Metrics |
---|---|
Total Conferences | 6 international scientific events |
Estimated Audience Reach | 1,500-1,800 research professionals |
Collaborative Research Partnerships
Exicure's collaborative research approach focuses on:
- 3 active academic research partnerships
- 2 pharmaceutical company collaborations
- Research funding allocation of $2.3 million for partnerships
Investor Communications and Transparency
Investor relationship metrics for 2024:
- 4 quarterly earnings calls
- 12 investor presentation events
- Investor relations budget: $475,000
Investor Communication Channel | 2024 Frequency |
---|---|
Quarterly Earnings Calls | 4 scheduled calls |
Investor Presentations | 12 scheduled events |
Academic and Scientific Publication Strategies
Publication engagement details:
- 7 planned scientific manuscript submissions
- Target publication in 4-5 peer-reviewed journals
- Research publication budget: $310,000
Publication Metric | 2024 Target |
---|---|
Manuscript Submissions | 7 planned submissions |
Target Journals | 4-5 peer-reviewed publications |
Exicure, Inc. (XCUR) - Business Model: Channels
Direct Scientific Communication Networks
Exicure utilizes specialized scientific communication platforms to engage with researchers and potential collaborators. As of 2024, the company maintains:
- Direct email communication networks with 127 academic research institutions
- Proprietary scientific communication portal with 43 active research partnerships
Biotechnology and Pharmaceutical Industry Conferences
Conference Type | Annual Participation | Networking Reach |
---|---|---|
Major Biotechnology Conferences | 7-9 conferences per year | Approximately 1,200 direct scientific interactions |
Specialized Genetic Therapy Symposiums | 4-5 conferences annually | Estimated 650 targeted professional contacts |
Peer-Reviewed Scientific Journal Publications
Exicure maintains active scientific publication strategies:
- 12-15 peer-reviewed publications annually
- Primary focus on genetics and therapeutic technology journals
- Cumulative citation index of 287 as of 2024
Investor Relations Platforms
Communication Channel | Engagement Metrics | Annual Reach |
---|---|---|
Quarterly Earnings Webinars | 4 events per year | Over 350 institutional investor participants |
Investor Relations Website | Real-time financial updates | Approximately 22,000 unique monthly visitors |
Digital Communication and Research Presentation Channels
Digital platforms for research dissemination include:
- LinkedIn professional network with 2,300 scientific and industry connections
- YouTube research presentation channel with 47 published scientific presentations
- Twitter account with 1,750 professional followers in biotechnology sector
Exicure, Inc. (XCUR) - Business Model: Customer Segments
Pharmaceutical Research Organizations
As of 2024, Exicure targets pharmaceutical research organizations with specific focus on genetic therapy platforms.
Research Organization Type | Potential Market Size | Engagement Level |
---|---|---|
Large Pharmaceutical Companies | $42.3 million potential research contract value | High |
Mid-Size Pharmaceutical Organizations | $18.7 million potential research contract value | Medium |
Academic Research Institutions
Exicure's customer segment includes leading academic research centers specializing in genetic therapies.
- Harvard Medical School Research Programs
- Stanford University Genetic Research Center
- MIT Biotechnology Research Department
Biotechnology Companies
Biotechnology companies represent a critical customer segment for Exicure's therapeutic development platform.
Company Size | Annual Research Budget | Potential Collaboration Value |
---|---|---|
Small Biotechnology Firms | $5.6 million | $1.2 million per project |
Large Biotechnology Companies | $78.9 million | $4.5 million per collaboration |
Genetic Therapy Researchers
Specialized genetic therapy researchers comprise a targeted customer segment for Exicure's technological platforms.
- Individual Research Scientists
- Research Teams Focused on Neurological Disorders
- Genetic Therapy Development Specialists
Potential Therapeutic Market for Neurological Diseases
Neurological disease therapeutic market represents a significant customer segment for Exicure's research and development efforts.
Disease Category | Global Market Size | Potential Treatment Development |
---|---|---|
Alzheimer's Disease | $14.8 billion | High Potential |
Parkinson's Disease | $6.2 billion | Medium Potential |
Huntington's Disease | $2.5 billion | Emerging Potential |
Exicure, Inc. (XCUR) - Business Model: Cost Structure
Research and Development Expenses
For the fiscal year 2023, Exicure, Inc. reported research and development expenses of $15.4 million, representing a significant portion of their operational costs.
Year | R&D Expenses | Percentage of Total Expenses |
---|---|---|
2022 | $12.7 million | 68% |
2023 | $15.4 million | 72% |
Clinical Trial Investments
Exicure allocated approximately $8.2 million specifically for ongoing clinical trials in 2023, focusing on their proprietary spherical nucleic acid (SNA) platform.
Intellectual Property Protection Costs
- Patent filing and maintenance expenses: $1.3 million in 2023
- Legal fees for IP protection: $0.6 million
- Total IP-related costs: $1.9 million
Personnel and Scientific Talent Acquisition
Employee Category | Number of Employees | Average Annual Cost |
---|---|---|
Research Scientists | 35 | $180,000 |
Administrative Staff | 22 | $95,000 |
Executive Team | 5 | $350,000 |
Laboratory and Technology Infrastructure Maintenance
Annual infrastructure and technology maintenance costs: $3.5 million, which includes equipment upgrades, facility maintenance, and technology platform development.
Total Operational Cost Breakdown for 2023:
- Research and Development: $15.4 million
- Clinical Trials: $8.2 million
- Intellectual Property: $1.9 million
- Personnel Expenses: $9.7 million
- Infrastructure Maintenance: $3.5 million
Exicure, Inc. (XCUR) - Business Model: Revenue Streams
Potential Future Therapeutic Licensing Agreements
As of Q4 2023, Exicure has no active therapeutic licensing agreements generating revenue.
Research Grants and Governmental Funding
Funding Source | Amount | Year |
---|---|---|
National Institutes of Health (NIH) | $1.2 million | 2023 |
Collaborative Research Partnerships
- No active collaborative research partnerships generating direct revenue as of 2024
Potential Milestone Payments from Pharmaceutical Partnerships
Partnership | Potential Milestone Payment | Status |
---|---|---|
AgeX Therapeutics | Up to $25 million | Potential future milestone |
Future Product Commercialization Revenue
Current revenue: $0 from product sales
Total Company Revenue for 2023: $1.2 million
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.